Skye Bioscience SKYE Income Statement (2012-2026)

NASDAQ SKYE
$1.07 -0.03 (-2.29%)
At close: Nov 16, 2026 · 4:00 PM EST
Reported Financials

Skye Bioscience Quarterly Income Statement

Periods 59 quarters
Latest Sep 2026

Skye Bioscience reported net income of $0.07M for the quarter ended Sep 2026. This income statement covers 59 quarters of results from Apr 2012 through Sep 2026, standardized by Business Quant from the company’s SEC filings.

Income StatementIncome Statement Apr2012 Jul2012 Oct2012 Jan2013 Apr2013 Jul2013 Oct2013 Dec2013 Apr2014 Jun2014 Sep2014 Dec2014 Mar2015 Jun2015 Sep2015 Dec2015 Mar2016 Jun2016 Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026 Sep2026
Revenue & cost
Revenue
Operating items
Depreciation & Amortization - TotalDep. & Amort. (Tot)
Research & DevelopmentR&D
1.11M1.27M1.43M1.78M1.54M1.18M1.79M1.25M1.59M1.95M4.08M4.88M7.79M7.20M14.34M9.36M11.47M7.94M3.94M1.32M
Selling, General & AdministrativeSG&A
1.35M1.62M1.79M1.14M1.54M1.92M1.21M2.24M2.49M4.21M4.33M4.64M4.55M4.56M3.91M3.91M3.43M4.74M3.87M3.66M
Restructuring CostsRestructuring
-0.36M
Other Operating ExpensesOther Opex
-6.21M-0.15M-4.55M-1.68M3.25M-5.00M
Operating ExpensesOpex
2.46M2.89M3.22M2.92M9.28M3.10M2.84M24.71M4.09M6.15M8.41M4.97M10.67M11.76M18.24M13.26M14.90M12.67M11.06M-0.03M
Operating IncomeOp. Inc
-2.46M-2.89M-3.22M-2.92M-9.28M-3.10M-2.84M-24.71M-4.09M-6.15M-8.41M-4.97M-10.67M-11.76M-18.24M-13.26M-14.90M-12.67M-11.06M0.03M
Non-operating items
Non Operating Interest Expenses
0.20M0.20M0.21M0.21M0.05M0.02M0.19M0.27M0.43M0.44M0.45M-0.09M-0.05M0.00M0.00M0.00M0.00M
Gains (Losses) on Sale of Assets & InvestmentsGains on Sales
-0.31M1.15M0.07M0.14M0.09M0.09M0.18M0.18M
Interest & Investment IncomeInt & Inv Inc
0.02M0.02M0.01M0.02M0.05M0.43M0.96M0.91M0.73M0.62M0.53M0.42M0.27M0.17M0.10M0.05M
Other Non Operating IncomeOther Non Op Inc.
-0.04M-3.000.00M-359.00-801.000.04M-502.000.00M0.00M
Non Operating IncomeNon Op. Inc.
-0.05M-0.16M-0.20M-0.21M-0.61M-2.07M-0.26M-0.24M-0.33M1.13M0.51M1.07M0.92M0.66M0.62M0.51M0.45M0.17M0.28M0.04M
Net income details
EBIT
-2.46M-2.89M-3.22M-2.92M-9.28M-3.10M-2.84M-24.71M-4.09M-6.15M-8.41M-4.97M-10.67M-11.76M-18.24M-13.26M-14.90M-12.67M-11.06M0.03M
EBT
-2.51M-3.04M-3.41M-3.13M-9.89M-5.17M-3.11M-24.95M-4.42M-5.02M-7.89M-3.90M-9.75M-11.10M-17.62M-12.75M-14.44M-12.51M-10.78M0.07M
Tax ProvisionsTaxes
500.000.01M0.00M0.00M0.00M0.01M0.00M0.00M0.00M
Income After Tax
-2.51M-3.04M-3.42M-3.13M-9.89M-5.17M-3.11M-24.95M-4.42M-5.02M-7.90M-3.90M-9.75M-11.10M-17.62M-12.75M-14.44M-12.51M-10.79M0.07M
Income from Continuing OperationsIncome (Continuing)
-2.51M-3.04M-3.42M-3.13M-9.89M-5.17M-3.11M-24.95M-4.42M-5.02M-7.90M-3.90M-9.75M-11.10M-17.62M-12.75M-14.44M-12.51M-10.79M0.07M
Consolidated Net IncomeConsol Net Inc.
-2.51M-3.04M-3.42M-3.13M-9.89M-5.17M-3.11M-24.95M-4.42M-5.02M-7.90M-3.90M-9.75M-11.10M-17.62M-12.75M-14.44M-12.51M-10.79M0.07M
Income towards Parent CompanyParent Net Inc
-2.51M-3.04M-3.42M-3.13M-9.89M-5.17M-3.11M-24.95M-4.42M-5.02M-7.90M-3.90M-9.75M-11.10M-17.62M-12.75M-14.44M-12.51M-10.79M0.07M
Preferred Dividend PaymentsPref Dividends
Net Income towards Common StockholdersNet Income
-2.51M-3.04M-3.42M-3.13M-9.89M-5.17M-3.11M-24.95M-4.42M-5.02M-7.90M-3.90M-9.75M-11.10M-17.62M-12.75M-14.44M-12.51M-10.79M0.07M
Additional items
EPS (Basic)
-0.57-0.05-0.72-0.66-2.10-10.97-6.41-25.32-5.05-1.43-1.63-0.80-2.14-2.24-3.56-2.57-2.91-2.52-2.170.01
EPS (Diluted)
-0.05-0.05-0.06-0.05-0.14-0.04-0.03-25.32-5.05-1.43-1.63-0.80-2.14-2.24-3.56-2.57-2.91-2.52-2.170.01
Shares Outstanding
4.43M61.98M4.72M4.72M4.72M0.47M0.49M0.99M0.88M3.50M4.83M4.85M4.56M4.96M4.96M4.96M4.96M4.96M4.96M4.96M
Shares Outstanding (Diluted)Shares Outstanding (Dil.)
50.82M61.98M61.99M61.99M69.41M117.74M121.44M0.99M0.88M3.50M4.83M4.85M4.56M4.96M4.96M4.96M4.96M4.96M4.96M4.99M
Shares Outstanding (Entity)Shares Outstanding (Entity.)
4.43M61.98M4.72M0.47M0.49M0.99M0.88M3.51M4.83M4.85M3.87M4.96M4.96M4.96M4.17M4.39M4.39M4.42M
EBITDA
-2.28M-2.71M-3.19M-2.89M-9.24M-3.07M-2.81M-24.67M-3.83M-5.89M-8.37M-4.90M-10.49M-11.58M-18.06M-13.09M-14.72M-12.50M-10.90M0.06M
Interest ExpensesInt Expense
0.20M0.20M0.21M0.21M0.05M0.02M0.19M0.27M0.43M0.44M0.45M-0.09M-0.05M0.00M0.00M0.00M0.00M
Tax Rate

Skye Bioscience Income Statement API

Pull Skye Bioscience's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=SKYE&statement=IS&frequency=Quarter&period=all&api_key=YOUR_API_KEY